人类造血细胞的基因改造：用于临床试验的逆转录病毒介导基因转移的临床前优化
Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.
作者信息
Budak-Alpdogan Tulin, Rivière Isabelle
机构信息
Department of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA.
出版信息
Methods Mol Biol. 2009;506:33-58. doi: 10.1007/978-1-59745-409-4_4.
Abstract
This chapter provides information about the oncoretroviral transduction of human hematopoietic stem/ progenitor cells under clinically applicable conditions. We describe in detail a short -60 h transduction protocol which consistently yields transduction efficiencies in the range of 30-50% with five different oncoretroviral vectors. We discuss a number of parameters that affect transduction efficiency, including the oncoretroviral vector characteristics, the vector stock collection, the source of CD34+ cells and transduction conditions.
摘要
本章提供了在临床适用条件下人类造血干/祖细胞的嗜肝性逆转录病毒转导的相关信息。我们详细描述了一个为期60小时的简短转导方案，该方案使用五种不同的嗜肝性逆转录病毒载体，始终能产生30%-50%的转导效率。我们讨论了一些影响转导效率的参数，包括嗜肝性逆转录病毒载体特性、载体储备收集、CD34+细胞来源和转导条件。
相似文献
1
Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.
Methods Mol Biol. 2009;506:33-58. doi: 10.1007/978-1-59745-409-4_4.
2
Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells.
J Gene Med. 2001 May-Jun;3(3):219-27. doi: 10.1002/1521-2254(200105/06)3:3<219::AID-JGM184>3.0.CO;2-E.
3
Retrovirus-mediated gene transfer to human hematopoietic stem cells.
Methods Mol Med. 2002;69:187-202. doi: 10.1385/1-59259-141-8:187.
4
Efficient oncoretroviral transduction of extended long-term culture-initiating cells and NOD/SCID repopulating cells: enhanced reconstitution with gene-marked cells through an ex vivo expansion approach.
Hum Gene Ther. 2002 Jun 10;13(9):1061-73. doi: 10.1089/104303402753812467.
5
Transduction of human hematopoietic cells and cell lines using a retroviral vector containing a modified murine CD4 reporter gene.
Hum Gene Ther. 1997 Feb 10;8(3):243-52. doi: 10.1089/hum.1997.8.3-243.
6
Highly efficient gene transfer into preterm CD34 hematopoietic progenitor cells.
Am J Obstet Gynecol. 2000 Sep;183(3):732-7. doi: 10.1067/mob.2000.106752.
7
A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells.
Mol Ther. 2003 Nov;8(5):804-12. doi: 10.1016/j.ymthe.2003.07.002.
8
Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Gene Ther. 2005 Oct;12(19):1424-33. doi: 10.1038/sj.gt.3302562.
9
Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium.
Hum Gene Ther. 1998 Apr 10;9(6):771-8. doi: 10.1089/hum.1998.9.6-771.
10
Transduction of feline hematopoietic cells by oncoretroviral vectors pseudotyped with the subgroup A feline leukemia virus (FeLV-A).
Mol Ther. 2000 Jul;2(1):56-62. doi: 10.1006/mthe.2000.0090.
本文引用的文献
1
Methods for the construction of retroviral vectors and the generation of high-titer producers.
Methods Mol Med. 1997;7:59-78. doi: 10.1385/0-89603-484-4:59.
2
Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol.
Hum Gene Ther. 2006 Jul;17(7):780-94. doi: 10.1089/hum.2006.17.780.
3
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Cancer Gene Ther. 2006 Sep;13(9):886-95. doi: 10.1038/sj.cgt.7700963. Epub 2006 Apr 28.
4
Relationship between retroviral vector membrane and vector stability.
J Gen Virol. 2006 May;87(Pt 5):1349-1356. doi: 10.1099/vir.0.81302-0.
5
Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability.
Biotechnol Bioeng. 2006 Jun 5;94(2):322-9. doi: 10.1002/bit.20847.
6
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates.
J Exp Med. 2005 Dec 5;202(11):1599-611. doi: 10.1084/jem.20050967.
7
Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.
Gene Ther. 2006 Jan;13(1):95-100. doi: 10.1038/sj.gt.3302648.
8
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
Lancet. 2004;364(9452):2181-7. doi: 10.1016/S0140-6736(04)17590-9.
9
Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates.
Stem Cells. 2004;22(6):1062-9. doi: 10.1634/stemcells.22-6-1062.
10
Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy.
Biotechnol Prog. 2004 Jul-Aug;20(4):1198-203. doi: 10.1021/bp030065g.
Zotero 插件